Verdict91/ 100
Grade A− · #2Eden
A polished, high-disclosure compounded program with strong nationwide coverage.
Visit EdenHead-to-head verdict
Eden vs Sprout Health
Two GLP-1 providers, ruled side by side on The Verdict Score — our published six-factor rubric. Same yardstick, and no score is adjusted for payment.
vs
Verdict86/ 100
Grade B · #6Sprout Health
A LegitScript-certified desk that pairs low-cost compounded semaglutide and tirzepatide with a real brand-name Wegovy and Zepbound path — carrying an FDA warning letter from September 2025.
Visit Sprout HealthThe verdict
Winner: Eden
Eden takes it with a higher Verdict Score — 91/100 to 86/100 (grade A− vs B). People who prioritize a vetted, high-transparency provider over the lowest sticker price. Sprout Health still earns its place — patients who want a low compounded entry price but the option of brand-name Wegovy or Zepbound on the same account, with minimal onboarding.
Neither of these is our overall #1. That title goes to CoreAge Rx (94/100) — the most honest middle of the market: nationwide access, both molecules at one flat, no-surprise price.
Factor by factor
Both scored on the same six factors — see the methodology. The brass bar marks the stronger side on each.
90Real-world results82
90
Real-world results82
89Price honesty90
89
Price honesty90
95Prescriber access82
95
Prescriber access82
86Formulary choice86
86
Formulary choice86
90Cancellation fairness80
90
Cancellation fairness80
92Member support78
92
Member support78
Price, coverage & features
| Metric | Eden | Sprout Health |
|---|---|---|
| Verdict Score | 91/100 | 86/100 |
| Grade | A− | B |
| Semaglutide | $239/mo | $149/mo |
| Tirzepatide | $349/mo | $199/mo |
| Coverage | All 50 states | Not disclosed |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | No | No |
Eden
What we like
- High verification confidence — clear supply-chain and clinician disclosure
- Nationwide availability
- Both molecules offered
The caveats
- Premium pricing vs the cheapest tiers
- Compounded only — no brand-name access
- FDA issued a warning letter to Eden Health International Inc. dba Eden in June 2026; it is public in FDA's warning-letter database
Sprout Health
What we like
- LegitScript-certified with a listed address and contact line
- Both compounded ($149 semaglutide / $199 tirzepatide) and a genuine brand-name Wegovy/Zepbound route
- Low-friction intake — no labs and often no telehealth visit required
The caveats
- Compounded semaglutide and tirzepatide are not FDA-approved
- No oral or sublingual route — injectable only
- Thin transparency — no named medical director, and state availability is quiz-gated
- "No labs, no visit" convenience also means lighter clinical oversight
- FDA issued a warning letter to Sprout Health Partners LLC dba Sprout Health in September 2025; it is public in FDA's warning-letter database
Our pick — visit
People who prioritize a vetted, high-transparency provider over the lowest sticker price.
Visit Eden Read the full Eden review →Also worth a look
Patients who want a low compounded entry price but the option of brand-name Wegovy or Zepbound on the same account, with minimal onboarding.
Visit Sprout Health Read the full Sprout Health review →Keep comparing
Neither of these has to be the answer: the rivals we rank against Eden cover the 7 programs closest to it, and the same shortlist for Sprout Health does the reverse.
Or browse the full comparison hub and the complete rankings.
Pricing, states and verification reflect each provider's public disclosures at last review; the Verdict Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.